Cargando…

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population

Detalles Bibliográficos
Autores principales:	Pini, Jonathan, Moussaieff, Arieh, Murris, Emilie, Shalom-Feuerstein, Reuven, Petit, Isabelle, Aberdam, Daniel, Rouleau, Matthieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242259/ http://dx.doi.org/10.1186/1479-5876-9-S2-P31

Ejemplares similares

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
por: Chen, Gang, et al.
Publicado: (2018)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
por: Zhang, Yaqing, et al.
Publicado: (2017)

microRNA-184 Induces a Commitment Switch to Epidermal Differentiation
por: Nagosa, Sara, et al.
Publicado: (2017)

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
por: Su, Dandan, et al.
Publicado: (2019)

Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell
por: Huang, Chaoqun, et al.
Publicado: (2019)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
por: Mukherjee, Debayan, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

PD-L1 expression levels on tumor cells affect their immunosuppressive activity
por: Zheng, Yang, et al.
Publicado: (2019)

The Immunosuppressive Roles of PD-L1 during Influenza A Virus Infection
por: Ning, Hongya, et al.
Publicado: (2023)

Self-actuated biomimetic nanocomposites for photothermal therapy and PD-L1 immunosuppression
por: Li, Wenxin, et al.
Publicado: (2023)

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
por: Hiltbrunner, Stefanie, et al.
Publicado: (2023)

PD-1-stimulated T cell subsets are transcriptionally and functionally distinct
por: Lerrer, Shalom, et al.
Publicado: (2021)

S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
por: Grassmann, S, et al.
Publicado: (2014)

Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles
por: Deng, Jun, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(−)PD-L1(+) Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
por: Liu, Min, et al.
Publicado: (2021)

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
por: Mahoney, Kathleen M., et al.
Publicado: (2018)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer
por: Dong, Xinrui, et al.
Publicado: (2023)

Induced pluripotent stem cell-derived limbal epithelial cells (LiPSC) as a cellular alternative for in vitro ocular toxicity testing
por: Aberdam, Edith, et al.
Publicado: (2017)

Tong-fu-li-fei decoction attenuates immunosuppression to protect the intestinal-mucosal barrier in sepsis by inhibiting the PD-1/PD-L1 signaling pathway
por: Chen, Li, et al.
Publicado: (2021)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Multi-platform NMR Study of Pluripotent Stem Cells Unveils Complementary Metabolic Signatures towards Differentiation
por: Elena-Herrmann, Bénédicte, et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression
por: Sajiki, Yamato, et al.
Publicado: (2021)

Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1
por: Jung, Mi-Yeon, et al.
Publicado: (2022)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oh0tah9d7k8u7ufhkv6oc42gvc